Betaine and Folic Acid: study protocols
10 study groups took Betaine together with Folic Acid. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Betaine
10 study groups in 9 studies say how much Betaine participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 2.5 g to 5 g, 60% of 10 study groups.
| Daily dose | Study groups |
|---|---|
| 500 mg or less | 1 |
| 500 mg to 1 g | 1 |
| 1 g to 2.5 g | 0 |
| 2.5 g to 5 g | 6 |
| 5 g to 10 g | 1 |
| over 10 g | 1 |
Dose per serving from research: Folic Acid
10 study groups in 9 studies say how much Folic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 2.5 mg to 5 mg, 50% of 10 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mcg to 500 mcg | 2 |
| 500 mcg to 1 mg | 1 |
| 1 mg to 2.5 mg | 0 |
| 2.5 mg to 5 mg | 5 |
| 5 mg to 10 mg | 0 |
| 10 mg to 25 mg | 2 |
Commonly used together
6 of 10 study groups took Betaine and Folic Acid with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin B12 | 3 |
| Vitamin B6 | 3 |
10 study groups
| Study | ||||
|---|---|---|---|---|
| Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy 2000 · Folic acid 5 mg daily with betaine 4 g per day (12-week phase) · Adults on maintenance dialysis with end-stage renal disease and hyperhomocysteinemia | 4 g | 5 mg | 12 weeks | — |
| A study of the treatment of Rett syndrome with folate and betaine 2009 · Folate–betaine combination, participants weighing less than 30 kg · Females aged 1.2–28.9 years with Rett syndrome and a MECP2 gene mutation; participants in this dose subgroup weighed less than 30 kg | 6 g | 15 mg | 1 year | — |
| A study of the treatment of Rett syndrome with folate and betaine 2009 · Folate–betaine combination, participants weighing more than 30 kg · Females aged 1.2–28.9 years with Rett syndrome and a MECP2 gene mutation; participants in this dose subgroup weighed more than 30 kg | 12 g | 15 mg | 1 year | — |
| Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure 2002 · Folic acid, pyridoxine, and glycine betaine · Patients with chronic renal failure who were folate and pyridoxine replete | 4 g | 5 mg | 90 days | 36 |
| Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients 1999 · Folic acid 5 mg daily with betaine · Adults with end-stage renal disease receiving maintenance haemodialysis | 4 g | 5 mg | 12 weeks | — |
| No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients 1998 · 5 mg folic acid plus 4 g betaine (phase 1) · Haemodialysis patients with hyperhomocysteinaemia; age and sex not reported | 4 g | 5 mg | 12 weeks | — |
| Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy 1998 · 5 mg folic acid and 4 g betaine daily · Peritoneal dialysis patients with hyperhomocysteinemia | 4 g | 5 mg | 12 weeks | — |
| A novel nutritional supplement to reduce plasma homocysteine in nonpregnant women: A randomised controlled trial in The Gambia 2019 · drink powder · Nonpregnant, non-lactating healthy women aged 18–45 years in West Kiang, The Gambia; women of reproductive age with common micronutrient deficiencies in the population | 4 g | 800 mcg | 12 weeks | 93 |
| Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial 2016 · Normocis 400® group · Adults with stage 1 essential hypertension and hyper-homocysteinemia (HCys ≥15 μmol/L), without a history of cardiovascular or cerebrovascular disease; mean age 62.8 years, 63.5% male | 250 mg | 400 mcg | 60 days | 52 |
| Effects of low-dose B vitamins plus betaine supplementation on lowering homocysteine concentrations among Chinese adults with hyperhomocysteinemia: a randomized, double-blind, controlled preliminary clinical trial 2023 · supplement group · Chinese adults aged 18–65 with hyperhomocysteinemia (blood homocysteine 15–100 μmol/L) | 1 g | 400 mcg | 12 weeks | 44 |